Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Sponsor: National Cancer Institute (NCI)
A observational or N/A phase clinical study on Stage III Cutaneous Melanoma AJCC v7 and Stage IV Cutaneous Melanoma AJCC v6 and v7, this trial is ongoing. The trial is conducted by National Cancer Institute (NCI) and has accumulated 96 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)PRIMARY OBJECTIVE: I. To compare progression-free survival with intermittent dosing and continuous dosing of dabrafenib and trametinib among patients with metastatic BRAF V600E/K mutant melanoma. SECONDARY OBJECTIVES: I. To estimate the frequency and severity of toxicities of the two dosing schedules. II. To compare the frequency and severity of fever \>= grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) 4.0 of the two dosing schedules. III. To compare the response rate (complete and partial response, confirmed and unconfirmed), overall survival, and survival after progression between the two dosing schedules on step 2. TRANSLATIONAL MEDICINE OBJECTIVES: I. To evaluate whether acquired molecular events leading to reactivation of the MAPK pathway are more common among patients on the continuous dosing arm than on the intermittent dosing arm using circulating tumor deoxyribonucleic acid (DNA) (ctDNA). II. To assess the prognostic association between baseline biomarkers and early molecular events with progression free survival (PFS). III. To explore the potential interaction between treatment arm and baseline biomarkers/early molecular events with PFS. IV. To bank tissue and whole blood in anticipation of future studies to evaluate molecular events associated with clinical benefit and disease progression in patients treated with continuous versus intermittent dabrafenib and...
PRIMARY OBJECTIVE:
I. To compare progression-free survival with intermittent dosing and continuous dosing of dabrafenib and trametinib among patients with metastatic BRAF V600E/K mutant melanoma.
SECONDARY OBJECTIVES:
I. To estimate the frequency and severity of toxicities of the two dosing schedules.
II. To compare the frequency and severity of fever \>= grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) 4.0 of the two dosing schedules.
III. To compare the response rate (complete and partial response, confirmed and unconfirmed), overall survival, and survival after progression between the two dosing schedules on step 2.
TRANSLATIONAL MEDICINE OBJECTIVES:
I. To evaluate whether acquired molecular events leading to reactivation of the MAPK pathway are more common among patients on the continuous dosing arm than on the intermittent dosing arm using circulating tumor deoxyribonucleic acid (DNA) (ctDNA).
II. To assess the prognostic association between baseline biomarkers and early molecular events with progression free survival (PFS).
III. To explore the potential interaction between treatment arm and baseline biomarkers/early molecular events with PFS.
IV. To bank tissue and whole blood in anticipation of future studies to evaluate molecular events associated with clinical benefit and disease progression in patients treated with continuous versus intermittent dabrafenib and trametinib.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I (CONTINUOUS DOSING): Patients receive dabrafenib orally (PO) twice daily (BID) and trametinib PO once daily (QD) on days 1-56 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients also undergo positron emission tomography/computed tomography (PET/CT) or CT scans in week 1 of cycle 2 and at off treatment follow up prior to progression. Additionally, patients undergo blood sample collection, echocardiography (ECHO) or multigated acquisition scan (MUGA) on study.
ARM II (INTERMITTENT DOSING): Patients receive dabrafenib PO BID and trametinib PO QD on days 1-7 and 29-56 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT or CT scans in week 1 of cycle 2 and at off treatment follow up prior to progression. Additionally, patients undergo blood sample collection, ECHO or MUGA on study.
After completion of study treatment, patients are followed up every 6 months for 3 years and then yearly for 2 years.
Status Flow
Change History
96 versions recorded-
Apr 13, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE2 → None
-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE2
▶ Show 91 earlier versions
-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE2
-
Dec 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE2
-
Feb 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
-
Sep 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
Jul 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE2
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE2
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Mar 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE2
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE2
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE2
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE2
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Mar 2017 — Apr 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This phase II trial compares the effect of dabrafenib and trametinib given continuously to given with a break in treatment (intermittent) in treating patients with stage III-IV melanoma that cannot be removed by surgery and contains a B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving dabrafenib and trametinib with intermittent dosing may be as effect as when given continuously in treating patients with stage III-IV melanoma with a BRAF mutation that cannot be removed by surgery.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .